Results 61 to 70 of about 1,686,994 (258)

Prevalence of the Helicobacter pylori infection in chronic urticaria [PDF]

open access: yes
Background Urticaria is one of the most common clinically diagnosed dermatologic diseases. Wheals and pruritus are typical presentation of disease. Correlation between chronic urticaria (CU) and Helicobacter pylori infection has been proposed by many ...
رستمی مقدم, مجید
core  

Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system [PDF]

open access: yes, 2016
Mona Al-Ahmad,1 Maryam S Alowayesh,2 Norman V Carroll31Microbiology Department, Faculty of Medicine, 2Pharmacy Practice Department, Faculty of Pharmacy, Kuwait University, Kuwait; 3Division of Pharmacoeconomics and Health Outcomes, School of Pharmacy ...
Al-Ahmad M, Carroll NV, Alowayesh MS
core  

Histaminergic angioedema and chronic urticaria

open access: yes, 2015
International audienceMost angioedemas are histaminergic and correspond to deep urticarial swelling. Recurrent histaminergic angioedema led to the diagnosis of chronic urticaria, even when there are no superficial associated hives. Chronic urticaria is a
Nosbaum, Audrey   +6 more
core   +1 more source

Chronic Urticaria in Older Adults: Treatment Considerations

open access: yes, 2023
: Chronic urticaria is characterized by recurrent wheals and/or angioedema lasting for more than 6 weeks. Chronic urticaria is an extremely disabling disease limiting daily activities, compromising patient quality of life, and frequently associated with ...
Cillo, Francesco   +5 more
core   +1 more source

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem   +5 more
wiley   +1 more source

Advances in Understanding and Managing Chronic Urticaria [version 1; referees: 2 approved]

open access: yesF1000Research, 2016
There have been recent advances in the classification and management of chronic urticaria. The new term chronic spontaneous urticaria (CSU) has replaced chronic idiopathic urticaria and chronic autoimmune urticaria.
Yasmin Moolani   +2 more
doaj   +1 more source

Evaluation, diagnosis and management of chronic urticaria

open access: yes, 2014
Background Urticaria produces weals, which are itchy and can affect the quality of life and social functioning of an affected patient. There are several different subtypes of urticaria. This article focuses on chronic urticaria.
Perera, Eshini, Sinclair, Rodney
core  

Chronic Spontaneous Urticaria and Comorbidities

open access: yes
77107Chronic spontaneous urticaria (CSU) is a common and debilitating disease, which frequently coexists with other diseases, i.e., comorbidities. Some comorbidities, e.g., autoimmune diseases, are more common in CSU patients, and CSU patients may ...
Kolkhir, P. V., Maurer, Marcus
core   +1 more source

N‐acetylcysteine for non‐paracetamol‐induced acute liver failure in children: A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Non‐surgical treatment of acute liver failure (ALF) is primarily supportive and depends on the underlying cause. While N‐acetylcysteine (NAC) is proven effective in paracetamol‐induced ALF, its potential benefits in non‐paracetamol ALF for paediatric patients remain unclear.
Alise D. E. de Groot   +7 more
wiley   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy